Table 1 Patient Characteristics
From: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Characteristics | All | Patients | Patients | analyzed | P value |
|---|---|---|---|---|---|
| Â | No. | Percent | No. | Percent | Â |
Age, (yrs) | Â | Â | Â | Â | Â |
   Median(IQR) | 49.0 (46.5-51.4) | 49.5 (46.8-52.3) | P > 0.05 | ||
   Range | 26-75 | 26-75 |  | ||
EOCG performance status | Â | Â | Â | Â | Â |
   0 | 12 | 17.9% | 10 | 17.5% | P > 0.05 |
   1 | 49 | 73.1% | 45 | 79.0% |  |
   2 | 6 | 9.0% | 2 | 3.5% |  |
Hormone receptor status | Â | Â | Â | Â | Â |
   ER(+) or PR(+) or Both | 29 | 43.3% | 25 | 43.8% | P > 0.05 |
   ER(-) and PR(-) | 38 | 56.7% | 32 | 56.2% |  |
HER2 expression by IHC | Â | Â | Â | Â | Â |
   1+/2+ (HER2 status confirmed by FISH) | 22 | 32.8% | 20 | 35.1% | P > 0.05 |
   3+ positive | 45 | 67.2% | 37 | 64.9% |  |
Number of involved sites | Â | Â | Â | Â | Â |
   1 | 16 | 23.9% | 13 | 22.8% | P > 0.05 |
   2 | 23 | 34.3% | 22 | 38.6% |  |
   ≥3 | 28 | 41.8% | 22 | 38.6% |  |
Location of involved sites | Â | Â | Â | Â | Â |
   Visceral only | 19 | 28.4% | 16 | 28.1% | P > 0.05 |
   Visceral and nonvisceral | 34 | 50.7% | 29 | 50.9% |  |
   Nonvisceral only | 14 | 20.9% | 12 | 21.0% |  |
Involved organs | Â | Â | Â | Â | Â |
   Lung | 29 | 43.3% | 26 | 45.6% | P > 0.05 |
   Liver | 26 | 38.8% | 23 | 40.4% |  |
   Brain | 18 | 26.9% | 14 | 24.6% |  |
Previous chemotherapy regimens | Â | Â | Â | Â | Â |
   1 | 16 | 23.9% | 13 | 22.8% | P > 0.05 |
   2 | 22 | 32.8% | 20 | 35.1% |  |
   ≥3 | 29 | 43.3% | 24 | 42.1% |  |
Previous capecitabine | Â | Â | Â | Â | Â |
   YES |  |  |  |  |  |
Progression during capecitabine | 35 | 52.2% | 29 | 50.9% | P > 0.05 |
No Progression during capecitabine | 11 | 16.4% | 10 | 17.5% | Â |
   NO | 21 | 31.3% | 18 | 31.6% |  |